The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | TIDAL and COASTAL: zandelisib for the treatment of R/R FL and MZL
Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland talks on the Phase II TIDAL trial (NCT03768505) in which the safety and efficacy of zandelisib, a P13K inhibitor, was assessed in patients with relapsed/refractory follicular lymphoma (R/R FL) or marginal zone lymphoma (MZL) after failure of at least two prior lines of systemic therapy. Moreover, Prof. Jurczak discusses the randomised, Phase III COASTAL trial (NCT04745832) in which zandelisib plus rituximab is compared to standard chemoimmunotherapy in patients with R/R FL or R/R MZL. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
